MGC Pharmaceuticals d.o.o
Quick facts
Marketed products
- ArtemiC
ArtemiC is a cannabis-based pharmaceutical product that delivers cannabinoids for therapeutic effect.
Phase 3 pipeline
- CimetrA-1 · Neurology / Immunology
CimetrA-1 is a cannabinoid-based therapeutic that modulates endocannabinoid system signaling to produce anti-inflammatory and neuroprotective effects. - CimetrA-2 · Pain management
CimetrA-2 is a synthetic cannabinoid receptor agonist.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: